Pentetic Acid

Pentetic Acid

SCHEMBL9440488

NCCCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)C(=O)O.O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC15A2 Q16348 1/20 0.51
NTSR1 P30989 8/20 0.48
ERAP2 Q6P179 1/20 0.47
LNPEP Q9UIQ6 1/20 0.47
CHRND Q07001 6/20 0.47
CHRNA1 P02708 2/20 0.47
CHRNG P07510 2/20 0.47
CHRNB1 P11230 2/20 0.47
NPY1R P25929 1/20 0.45
NPY2R P49146 1/20 0.45
NPY4R P50391 1/20 0.45
ITGB3 P05106 1/20 0.44
ITGA2B P08514 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL306050 0.91 FOLH1 (0.50) NTSR1CHRNDCHRNA1CHRNGCHRNB1
SCHEMBL19211966 0.90 FOLH1 (0.49) NTSR1CHRNDCHRNA1CHRNGCHRNB1
SCHEMBL9318080 0.90 SLC15A2 (0.60) SLC15A2ERAP2LNPEPCHRNDCHRNA1
SCHEMBL9318061 0.90 SLC15A2 (0.60) SLC15A2ERAP2LNPEPCHRNDCHRNA1
SCHEMBL7122844 0.89 SLC15A2 (0.59) SLC15A2ERAP2LNPEPCHRNDCHRNA1
SCHEMBL7122854 0.89 SLC15A2 (0.59) SLC15A2ERAP2LNPEPCHRNDCHRNA1
SCHEMBL29980121 0.86 SLC15A2 (0.54) SLC15A2ERAP2LNPEPCHRNDCHRNA1
SCHEMBL9715437 0.85 CHRND (0.44) LNPEPCHRNDCHRNA1CHRNGCHRNB1
SCHEMBL29630584 0.83 CHRND (0.53) SLC15A2ERAP2LNPEPCHRNDCHRNA1
SCHEMBL18064482 0.83 CHRND (0.40) NTSR1ERAP2LNPEPCHRNDCHRNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0353295-B1 NOVEL AND IMPROVED ANTIBODIES FOR SITE SPECIFIC ATTACHMENT OF COMPOUNDS CYTOGEN CORP (US) 1994-04-06 EP claimed
EP-0173629-B1 ANTIBODY-METAL ION COMPLEXES CYTOGEN CORPORATION (US) 1992-06-10 EP claimed
EP-0382796-A4 METHOD FOR THE PREPARATION OF ANTIBODY-FRAGMENT CONJUGATES 1991-08-28 EP claimed
EP-0382796-A1 METHOD FOR THE PREPARATION OF ANTIBODY-FRAGMENT CONJUGATES CYTOGEN CORPORATION (US) 1990-08-22 EP claimed
US-4937183-A Therapy, diagnostis immunology CYTOGEN CORPORATION (US) 1990-06-26 US claimed
WO-1989007269-A1 METHOD FOR THE PREPARATION OF ANTIBODY-FRAGMENT CONJUGATES CYTOGEN CORPORATION (US) 1989-08-10 WO claimed
US-4741900-A Antibody-metal ion complexes CYTOGEN CORPORATION (US) 1988-05-03 US claimed
WO-1986001410-A1 ANTIBODY-METAL ION COMPLEXES CYTOGEN CORPORATION (US) 1986-03-13 WO claimed
EP-0173629-A1 Antibody-metal ion complexes CYTOGEN CORPORATION (US) 1986-03-05 EP claimed
EP-0173629-B1 ANTIBODY-METAL ION COMPLEXES CYTOGEN CORPORATION (US) 1992-06-10 EP disclosed
US-4741900-A Antibody-metal ion complexes CYTOGEN CORPORATION (US) 1988-05-03 US disclosed
EP-0173629-A1 Antibody-metal ion complexes CYTOGEN CORPORATION (US) 1986-03-05 EP disclosed